Lihua Yu
About Lihua Yu
Lihua Yu is the Chief Data Officer with a Ph.D. in biomedical engineering from Boston University and extensive experience in drug discovery and data science.
Professional Title: CDO
Lihua Yu serves as the Chief Data Officer (CDO). In this role, Yu is responsible for overseeing data management and the strategic integration of data science across research and development functions. Her contributions focus on ensuring data-driven decision-making processes within the organization.
Education and Expertise in Biomedical Engineering
Lihua Yu holds a Ph.D. in biomedical engineering from Boston University, where she studied under the mentorship of Dr. Temple Smith. She also earned a Master's of Engineering (M.E.) and a Bachelor's of Engineering (B.E.) in biomedical engineering from Tsinghua University in Beijing, China. Yu's extensive educational background provides a solid foundation for her work in biomedical and data science fields.
Background in Data Science Leadership
Lihua Yu has held several prominent positions where she demonstrated leadership in data science. She previously led the Data Science function at Fog Pharma, co-leading the discovery platform and identifying new targets. Additionally, Yu has served as Chief Data Science Officer and President at H3 Biomedicine and was the cancer bioinformatics leader at AstraZeneca Oncology US. Her roles showcased her skills in data integration and application in drug discovery and translational medicine.
Extensive Experience in Drug Discovery
Lihua Yu's career is marked by extensive experience in various stages of drug discovery, ranging from target identification to early clinical development. Her work spans data science, bioinformatics, and translational medicine, demonstrating a comprehensive understanding of the drug development pipeline. This expertise is integral to driving innovative approaches in biomedical research.
Passion for Integrating Data Science Across R&D
Lihua Yu is passionate about the integration and application of data science throughout the research and development lifecycle. Her commitment to this field is evident through her previous roles and her focus on leveraging data to enhance decision-making and accelerate drug discovery processes. This passion underpins her strategic vision for data-driven R&D advancements.